相关实验视频
Updated: May 1, 2026
16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.2K
用左心室辅助装置进行目的地治疗的最低数据集:对决策者来说重要的证据
Janet Puñal-Riobóo1, Maria José Faraldo Vallés1, Natalia Nogueira Uzal2
1Galician Health Knowledge Agency (Avalia-t ACIS), Santiago de Compostela, Spain.
International journal of technology assessment in health care
|January 17, 2025
概括
对于左心室辅助器件 (LVAD) 目的地治疗注册表,建立了一个最小数据集 (MDS). 这种标准化的数据收集改善了高级心力衰竭患者的决策和实践质量.
科学领域:
- 心脏病学 心脏病学
- 医疗器械技术 医疗器械技术
- 卫生技术评估 卫生技术评估
背景情况:
- 左心室辅助器件 (LVAD) 为不适合移植的晚期心力衰竭 (HF) 患者提供了一个治疗选择,作为目的地治疗 (DT).
- 关于LVADs的长期实际应用和结果仍然存在重大不确定性.
- 选择适当的结果对于注册表规划至关重要,以确保可比性并最大限度地减少偏差.
研究的目的:
- 为所有DT注册表的LVAD建立一个最小数据集 (MDS).
- 为了满足卫生技术评估 (HTA) 专业人员和医疗保健提供者的数据要求.
主要方法:
- 根据现有的HTA证据,并确定了研究缺陷,制定了结果领域和数据项的初步列表.
- 与经验丰富的心脏病专家一起进行了三轮的Delphi过程,以评估数据项对解决不确定性的重要性.
- 在七个关键领域的十八个结果和四十七个变量上达成共识.
主要成果:
- 专家小组就LVAD DT注册表的全面MDS达成共识.
- 该MDS包括十八个结果和四十七个变量,分为七个领域:安全性,有效性,患者接受度,满意度,医疗保健系统影响,药物管理和技术相关因素.
结论:
- 开发的MDS标准化了对LVAD目标治疗的数据收集.
- 这种标准化提高了数据质量,支持更好的决策和临床实践.
- 通过结构化数据集解决研究缺陷,改善了对LVADs在现实环境中的评估.
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753